Yale School of Medicine's dean
AbbVie compensation: $335,929
AbbVie shares value: $4,294,612
Alpern joined AbbVie's board in 2013 and has led Yale's medical school for more than a decade after becoming dean in 2004.
In 2014, with Alpern serving in both roles, AbbVie and the Yale School of Medicine agreed to a five-year, $14.5 million research deal. A story in Medicine at Yale,
a publication by the medical school's communications office, did not reference Alpern's relationship with AbbVie.
The dean's biography page on the school's website does not disclose his directorship at AbbVie.
In response to questions, a Yale spokesperson stated its conflict of interest policies "preserve the independence of our faculty and reduce the potential for real or perceived bias in our research activities, clinical decision-making,
and educational programs."
"If ever Dean Alpern had the opportunity to be involved in a decision affecting AbbVie, he would recuse himself," the spokesperson wrote.